JZP-898

N/A

Report date: 2023/11/02 20:01:30

Base Information

Drug NameJZP-898
Drug Alias Nameengineered IFN⍺2b cytokine pro-drug(Werewolf Therapeutics)WTX-613JZP898JZP-898
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon alpha replacements
TargetsInterferon alpha
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesWerewolf Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesJazz Pharmaceuticals PlcWerewolf Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A